Literature DB >> 4045244

Distribution and activity of amphotericin B in humans.

K J Christiansen, E M Bernard, J W Gold, D Armstrong.   

Abstract

Concentrations of amphotericin B (AmB) in tissues obtained at autopsy from eight patients were measured by high-performance liquid chromatography (HPLC). The patients had received doses of 101-2,688 mg of antibiotic. Highest concentrations of the drug were found in the liver; in one patient the amount of AmB in the liver was 41% of the total dose. No evidence of metabolism of the drug was observed, and bioassay of ethanol extracts of tissue showed that the drug retained activity. Three of the patients had histologic evidence of aspergillar or candidal infection in tissues with concentrations of AmB ranging from 2.5 to 166 micrograms/g. With two patients, the concentrations of the drug in the tissues exceeded by greater than or equal to 10-fold the minimum inhibitory concentrations of the drug in isolates that had been obtained from the same tissues. Unknown factors present in tissues appear to limit the in vivo activity of AmB.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045244     DOI: 10.1093/infdis/152.5.1037

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

2.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.

Authors:  S W Sanders; K N Buchi; M S Goddard; J K Lang; K G Tolman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Phagocytes, antibiotics and intracellular parasites: are the experimental data clinically relevant?

Authors:  J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

5.  Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.

Authors:  C Roth; J Gebhart; G Just-Nübling; B von Eisenhart-Rothe; I Beinhauer-Reeb
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

Review 6.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

7.  Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Emilio Mayayo; Valentina Salas; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

8.  Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.

Authors:  J A Vazquez; M T Arganoza; D Boikov; S Yoon; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 9.  Pharmacokinetic justification of antiprotozoal therapy. A US perspective.

Authors:  J D Berman; L Fleckenstein
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

10.  Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.

Authors:  E Martin; U Schlasius; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.